OpenScience.ink

2 weeks ago • Journal of diabetes and metabolic disorders

Short-term cost-effectiveness of tirzepatide, semaglutide, and liraglutide for treating obesity and overweight without diabetes in IranEconomic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.

📖 Top 50% JournalArticle

2 weeks ago • Hormones (Athens, Greece)

New diabetes medicines being developedAntidiabetic medications in the pipeline.

📖 Top 30% JournalArticle

2 weeks ago • Innere Medizin (Heidelberg, Germany)

Treating Type 2 Diabetes[Treatment of type 2 diabetes mellitus].

English Abstract

2 weeks ago • British journal of clinical pharmacology

How Elecoglipron is Absorbed in Healthy People When Taken With or Without FoodPhase 1, open-label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions.

📖 Top 20% JournalArticle

2 weeks ago • Journal of the American Society of Nephrology : JASN

Drugs that Activate Glucagon-Like Peptide-1 and Other Hormone Receptors for Protecting Kidneys in People Without DiabetesGlucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease.

Article

2 weeks ago • Diabetes, obesity & metabolism

Weight regain after hormone treatment: possible link to low muscle mass and benefits of adding testosterone in menWeight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men.

Article

2 weeks ago • Diabetes, obesity & metabolism

Changes in Muscle Strength Measured by Handgrip After Semaglutide Treatment in AdultsChanges in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta-Analysis of Handgrip Strength.

Article

2 weeks ago • Endocrine reviews

How Gut Bacteria and Fat Hormones Relate to Insulin Resistance Through Helpful and Harmful FGF21 and GDF15 SignalsThe Microbiome-Metabolokine-Adipokine Axis in Insulin Resistance: Adaptive and Maladaptive FGF21-GDF15 Signaling.

🥇 Top 1% JournalArticle

2 weeks ago • The lancet. Diabetes & endocrinology

The progress of obesity medicine: from early problems to WHO approvalThe development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO.

🥇 Top 1% JournalArticle

2 weeks ago • Cureus

Reducing Sleep Apnea Treatment After Weight Loss Caused by Diabetes MedicationDe-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review.

Article

2 weeks ago • Clinical, cosmetic and investigational dermatology

Safety of Energy-Based Treatments for Facial Aging Linked to GLP-1 Receptor Agonist Use in Different Skin TissuesEnergy-Based Devices for GLP-1 Receptor Agonist-Associated Facial Aging: A Tissue-Specific Safety Framework.

📖 Top 30% JournalArticle

2 weeks ago • Cureus

Duodenal Ulcer Hole After Tirzepatide Injections for Weight Loss: A Case ReportDuodenal Ulcer Perforation Following Tirzepatide Injections for Weight Loss Management: A Case Report.

Case Reports

2 weeks ago • Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

Healthcare costs and savings after weight-loss surgery or medication for obesity and diabetes depend on insurance coverageTotal healthcare costs and cost savings after bariatric surgery and glucagon-like peptide-1 receptor agonist treatment for obesity and diabetes vary with insurance coverage.

📖 Top 20% JournalArticle

2 weeks ago • Journal of plastic, reconstructive & aesthetic surgery : JPRAS

Timing of Starting and Stopping GLP-1 Treatment Around Tummy Tuck Surgery and Its Effects on Weight and ComplicationsPerioperative GLP-1 analog management in abdominoplasty: A multicenter comparative study of cessation and resumption timing on weight outcomes and complications.

📖 Top 30% JournalArticle

2 weeks ago • Diabetes, obesity, and cardiometabolic CARE

Physical activity habits in adults using GLP-1 receptor drugsPhysical Activity Patterns in Adults Taking Glucagon-Like Peptide 1 Receptor Agonists: An All of Us Cross-sectional Study.

Article

2 weeks ago • European journal of obstetrics, gynecology, and reproductive biology

Glucagon-like peptide-1 receptor agonists compared to metformin and their impact on pregnancy rates in women with polycystic ovary syndromeThe effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials.

Article

2 weeks ago • Diabetes, metabolic syndrome and obesity : targets and therapy

Adherence and Persistence with Injectable Compared to Oral GLP-1 Treatments in People with Type 2 DiabetesAdherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis.

📖 Top 30% JournalArticle

2 weeks ago • International journal of cardiology

GLP-1 receptor agonist treatment and new cases of irregular heartbeat in non-diabetic adults with obesity and kidney diseaseGLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.

Article

2 weeks ago • Body image

Links between positive body image, feeling connected to the body, and thoughts about GLP-1 weight loss treatment in UK womenAssociations between positive body image, embodiment, and GLP-1 consideration for weight loss among women in the United Kingdom.

🥉 Top 5% JournalArticle

2 weeks ago • Journal of shoulder and elbow arthroplasty

Safety of diabetes drug use in non-diabetic overweight patients having shoulder replacement surgeryEvaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty.

📖 Top 30% JournalArticle

2 weeks ago • Missouri medicine

Metabolic Surgery Compared to Glucagon-Like Peptide-1 Drugs for Treating Obesity and Related Health ProblemsThe Great Debate: Metabolic Surgery vs. Glucagon-Like Peptide-1 Receptor Agonists in Managing Patients with Obesity and its Related Comorbid Medical Illnesses.

📖 Top 50% JournalArticle

2 weeks ago • Diabetes, obesity, and cardiometabolic CARE

Changes in Diabetes Medicines After Metformin in Patients with High Compared to Moderate Heart Risk from 2014 to 2022Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014-2022.

Article

2 weeks ago • Cureus

Effectiveness, Safety, and Future Use of Hormone-Based Drugs for Treating ObesityModern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.

Article

2 weeks ago • Diabetes, obesity, and cardiometabolic CARE

Who Among U.S. Women of Childbearing Age Can Use GLP-1 Receptor Agonist TreatmentsGLP-1 RA Eligibility in Reproductive-Age U.S. Women.

Article

2 weeks ago • Frontiers in endocrinology

Accuracy, harm, weight bias, and commercial influence in short social media posts about obesity drugsAccuracy, potential harm, weight stigma, and commercial influence in short-form social media content on incretin-based therapies for obesity.

🎖️ Top 10% JournalArticle

2 weeks ago • Frontiers in endocrinology

Comparing CagriSema and Semaglutide 2.4 mg alone for weight loss in adults with overweight or obesity, with or without type 2 diabetesCagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

🎖️ Top 10% JournalSystematic Review

2 weeks ago • Alzheimer's & dementia (New York, N. Y.)

Effects of GLP-1 receptor drugs in Alzheimer's disease and mild memory problems: a combined analysisGLP-1 receptor agonists in Alzheimer's disease and MCI: a meta-analysis.

🥉 Top 5% JournalArticle

2 weeks ago • Kidney medicine

Key Treatments for Advanced Type 2 Diabetes and Severe Kidney Disease: Too Late or Still Possible to Start?Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible-or Not Too Late to Start?

📖 Top 20% JournalArticle

2 weeks ago • Clinical ophthalmology (Auckland, N.Z.)

Semaglutide use and risk of diabetic eye disease and optic nerve damage in type 2 diabetesSemaglutide Use and Risk of Diabetic Retinopathy and Non-Arteritic Anterior Ischemic Optic Neuropathy in Type 2 Diabetes: A Single-Center Retrospective Cohort Study.

📖 Top 20% JournalArticle

2 weeks ago • Cureus

Starting Glucagon-Like Peptide-1 Therapy and Lifestyle Changes for Severe Obesity in a Patient with Irregular Heartbeats, Joint Pain, and Sleep ApneaInitiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy and Lifestyle Modifications for Morbid Obesity in a Patient With Paroxysmal Atrial Fibrillation, Severe Osteoarthritis, and Obstructive Sleep Apnea: A Case Report.

Case Reports

← prevpage 9 of 16next →

Latest GLP-1 Therapies Research Papers